Skip to main content
Premium Trial:

Request an Annual Quote

Thermo Fisher Scientific Expects 12 Percent Revenue Growth in 2022

NEW YORK — Thermo Fisher Scientific on Friday provided initial revenue and earnings guidance for 2022, while reiterating previously disclosed financial guidance for full-year 2021.

In a presentation to investors, the company said it anticipates total revenues of $40.3 billion for next year, a 12 percent increase over its $35.9 billion in anticipated revenues for 2021. Adjusted earnings per share are expected to be $21.16. Wall Street analysts, on average, were projecting $34.3 billion in 2022 revenues and EPS of $19.68.

Thermo also reiterated 2021 guidance, provided in late July, of $35.9 billion of total revenue and adjusted EPS of $22.07.

The company's 2022 figures assume 8 percent core organic revenue growth and $750 million of COVID-19 testing response revenue, as well as $6.0 billion in revenue from clinical research services provider PPD, which Thermo Fisher is set to acquire by the end of 2021.

In April, when the company announced its plans to buy PPD for $17.4 billion in cash and the assumption of $3.5 billion in debt, it said that the acquisition would add $1.40 to its adjusted EPS in the first 12 months after the deal closed. On Friday, Thermo bumped that number up to $1.50.

Thermo Fisher also said that each additional $100 million of COVID-19 testing response revenue over the projected $750 million would add about $.06 of additional adjusted EPS.

Wall Street responded positively to the firm's 2022 guidance, pushing shares of the Waltham, Massachusetts-based company up 5 percent to $589.84 during morning trading on the New York Stock Exchange.

The Scan

Unique Germline Variants Found Among Black Prostate Cancer Patients

Through an exome sequencing study appearing in JCO Precision Oncology, researchers have found unique pathogenic or likely pathogenic variants within a cohort of Black prostate cancer patients.

Analysis of Endogenous Parvoviral Elements Found Within Animal Genomes

Researchers at PLOS Biology have examined the coevolution of endogenous parvoviral elements and animal genomes to gain insight into using the viruses as gene therapy vectors.

Saliva Testing Can Reveal Mosaic CNVs Important in Intellectual Disability

An Australian team has compared the yield of chromosomal microarray testing of both blood and saliva samples for syndromic intellectual disability in the European Journal of Human Genetics.

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.